Joseph R. Shaw: Thrombin Generation as a Pharmacodynamic Framework for Anticoagulant Therapy
Joseph R. Shaw, Director of Research+ Program at Ottawa Department of Medicine, EHJ-CVP Associate Editor at European Heart Journal, shared on LinkedIn about a recent article he and his colleagues co-authored, published in Pharmacological Reviews, adding:
”I’m pleased to share that our review, ‘Thrombin Generation and the Pharmacodynamics of Parenteral Anticoagulants’, is now published in Pharmacological Reviews.
It is a privilege to contribute this work to a leading journal with a strong tradition in mechanistic pharmacology.
Our findings underscore that parenteral anticoagulants influence thrombin generation and suggest that their effects are more class-specific than clinicians often appreciate.
Unfractionated heparin, low-molecular-weight heparins (LMWHs), fondaparinux, and parenteral direct thrombin inhibitors (DTIs; e.g., argatroban, bivalirudin) don’t simply produce interchangeable forms of ‘anticoagulation.’
They vary in their influence on coagulation initiation, amplification, and propagation, which may help explain why some agents are more effective than others in particular high-risk scenarios.
This framework also has broader implications for how we think about anticoagulants across classes.
For example, more complete suppression of thrombin generation by warfarin or heparin-based strategies may help explain why these agents remain preferred, or appear more effective, in settings such as mechanical heart valves, antiphospholipid syndrome, catheter-associated thrombosis, or breakthrough thrombosis.
By contrast, more selective inhibitors may offer greater pharmacodynamic consistency and relative preservation of endogenous thrombin potential, supporting their safety and effectiveness in many average-risk patients, while potentially making them more prone to failure under highly prothrombotic conditions – for example, ‘breakthrough’ stroke or thromboembolism.
Our aim is not to replace clinical outcome data but to provide a mechanistic complement that aids in its interpretation.
Thrombin generation offers a common pharmacodynamic framework for comparing anticoagulants, contextualizing epidemiologic and probabilistic signals, and understanding why clinical outcomes may diverge across drug classes and patient populations.
We hope this work helps build a stronger foundation for future research in comparative anticoagulation pharmacology – integrating mechanistic understanding with clinical evidence to facilitate more personalized anticoagulation decisions.”
Title: Thrombin generation and the pharmacodynamics of parenteral anticoagulants
Authors: Joseph R. Shaw, Cheryl L. Maier, Michaël Hardy, François Mullier, Jonathan Douxfils, Kenichi Tanaka, Bianca Rocca, Hugo ten Cate, Paul Y. Kim, Marc Carrier, Jean M. Connors, Jerrold H. Levy
Stay updated on all scientific advances with Hemostasis Today.
-
May 15, 2026, 16:42Gashaw Arega: Planning, Envisioning and Collaborating at Our ESPHO Office
-
May 15, 2026, 16:39Erin McMillen: ASH IGNITE Highlights the Power of Hematology Collaboration
-
May 15, 2026, 16:35David Murdock: Identifying High-Risk Variants of Uncertain Significance in Aortopathy Genes
-
May 15, 2026, 16:35Maeva May: How Do You Drive Global Change In Stroke? Check Out The WSO Report
-
May 15, 2026, 16:30Carl Robertson: 12 Evidence-Based Recommendations for Stroke Prevention in PFO
-
May 15, 2026, 16:27Lenae Goolsby: How We Target the Root Source of Joint Pain for Lasting Recovery
-
May 15, 2026, 16:22Shayan Mohammadmoradi: Supporting Cardiovascular Research Through Community Action
-
May 15, 2026, 16:10Sawrav Kr Sanyal: PE Prevention Through Lifestyle and Awareness
-
May 15, 2026, 15:54Seema Dawood: Morphologic Differences Between Platelet Types